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The new landscape of human transcriptome along with the identification of numerous long
non-coding RNAs (lncRNAs) has dramatically altered our approach to study diseases. It
is now imperative to decipher the biological functions of these transcripts and how they
impact on human cell and pathophysiology. Nonetheless, already at this very early stage of
their study, the involvement of lncRNAs in cell transformation is emerging as a key aspect.
Recently, researchers have started to explore the implications of lncRNAs alteration in
hepatic pathophysiology. In this review, we will discuss in detail several examples of liver
disease-relevant lncRNAs. Many lncRNAs have been shown to play a major role in hepato-
cellular carcinoma (HCC). For such type of tumor with an increasing incidence and a high
mortality rate, it is crucial to identify new therapeutic targets and biomarkers to predict
response to therapy. LncRNAs present as a promising new resource. One major challenge
for the future would be to systematically address the lncRNAs expression among the differ-
ent cellular components of the liver. To achieve this goal, a combination of clinically driven,
genetically defined, morphologically classified, and molecular-based studies will have to
be performed. In conclusion, lncRNAs will undoubtedly provide a rewarding field of study
and most importantly a new resource to identify new disease associated biomarkers and
molecular targets for therapy for liver diseases.
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INTRODUCTION
The ENCODE (Encyclopedia of DNA Elements) project has sub-
stantially contributed to reveal that more than 70% of the human
genome is transcribed (1), but only as few as the 2% of pro-
duced RNA is ultimately translated into proteins (2). The discovery
of numerous non-coding RNA (ncRNA) transcripts in humans
has dramatically altered our understanding of complex diseases
such as cancer. The scientific community now faces the challenge
to unravel the biological functions of these transcripts and to
understand how they impact on human cell physiology (2). In gen-
eral, ncRNAs are grouped into two major classes based on their
length. Those transcripts shorter of 200 nucleotides (nt) belong
to the class of small ncRNAs, mainly including Piwi-interacting
RNAs, small interfering RNAs, and microRNAs (miRNAs). Long
non-coding RNAs (lncRNAs) are mRNA-like transcripts ranging
in length from 200 nt to circa 100 kb, yet are poorly conserved
and do not function as templates for protein synthesis. How-
ever, more recently, among ncRNAs, the landscape of lncRNAs has
been unveiled by the fast progress of deep sequencing technology
Abbreviations: ENCODE, encyclopedia of DNA elements; HCC, hepatocellular
carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; HOTAIR, HOX tran-
script antisense RNA sequencing; HOTTIP, HOXA transcript at the distal tip;
HULC, highly upregulated in liver cancer; IGF2, insulin-like growth factor 2; IHC,
immunohistochemistry; kb, kilobase; MALAT-1, metastasis associated lung adeno-
carcinoma transcript 1; miRNAs, microRNA; ncRNA, non-coding RNA; NGS, next
generation sequencing; nt, nucleotides; ORF, open reading frame; PH, partial hepa-
tectomy; RNP, ribonucleoprotein; RNA pol II, RNA polymerase II; RNA-seq, RNA
sequencing; TUC338, transcribed ultra-conserved region 338.
along with the development of bioinformatics tools enabling their
identification (3). Based on their genomic proximity to protein-
coding genes, lncRNAs have been classified into four classes: exonic
lncRNAs, intronic lncRNAs, overlapping lncRNAs, and intergenic
lncRNAs. However, the definition of lncRNA, far for being com-
prehensive, is still under debate and rapidly changing as researchers
collect more information about them (4). Up to date, lncRNAs are
described as mRNA-like 5′-capped, polyadenylated RNAs tran-
scribed by the RNA polymerase II (RNA pol II) but with no evident
open reading frame (ORF), mostly acting to organize and direct
ribonucleoprotein (RNP) complexes, thus controlling gene expres-
sion (2, 4). LncRNAs are proposed to be the largest transcripts
class in the mouse and human transcriptomes. Several lncRNAs
have been shown to play essential roles in biological events such
as embryogenesis and tumorigenesis by regulating fundamental
cellular processes such as stress response, proliferation, differentia-
tion, and survival. Noteworthy, this class of genes have shown to be
poorly conserved across the species (5), and, differently from cod-
ing genes, their number seems to be directly related to the level of
organism complexity (2). Interestingly, according to the ENCODE
project data, the number of postulated lncRNAs should be higher
than protein-coding genes (4–6). One major characteristic of lncR-
NAs is their ability to fold into complex secondary structures,
something that is not feasible for short sequence RNAs such as
miRNAs, thus for example, enabling lncRNAs to provide docking
station for protein complexes aggregation (5). Although for the
majority of lncRNAs all potential functions and the mechanisms
of action are still undetermined, one major finding is that most
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lncRNAs show a tissue-specific pattern of expression and are as
well differentially abundant across several stages of development
(6). lncRNAs transcription indeed occurs in a tidily regulated man-
ner restricted both in time and space constraints (6). Among the
many functions that have been ascribed to lncRNAs, the following
are particularly noteworthy: decoy activity to bind and titrate away
proteins (7–9); guiding function to direct the localization of pro-
tein complexes to specific DNA region (10, 11), either in cis, thus
close by their genomic locus,as for example HOTTIP (HOXA tran-
script at the distal tip) (11), or in trans, controlling genomic distant
chromosomal region, e.g., HOTAIR (HOX Transcript Antisense
RNA) (12); acting as scaffold or adaptors providing a platform
for large molecular complexes assembly (13). In addition, sponge-
acting lncRNAs, able to sequester by binding and thus eventually
inhibiting miRNA activity (14, 15), have gained a lot of attention
in the field (16). However, whether this is a physiologically rele-
vant phenomenon or not is still under debate (16, 17). Recently,
a bunch of manuscripts have started to explore the implications
of lncRNAs alteration in hepatic pathophysiology (18). We will
discuss in detail several examples of liver disease relevant lncRNAs
in the next paragraphs. Since these genes do not code for proteins,
the role of their transcripts is challenging to be studied when func-
tional experiments are hard to be performed. For example, classical
loss of function approach using siRNA has been shown to be tricky
to be accomplished (19). At the same time, considering that many
lncRNA loci overlap with other genes, targeted gene recombi-
nation aiming to disrupt gene expression has also shown to be
problematic (19), thus resulting in hard to interpret phenotypes.
Exploring lncRNAs functions will be critical to fully appreciate
the relevance of these genes in the biological processes controlling
liver functionality. Nonetheless, already at this very early stage of
their study, the involvement of lncRNAs in cell transformation is
emerging as a key aspect (1).
lncRNAs IN HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related death worldwide and represents the majority of
liver cancers (80% circa of all cases) (20, 21). HCC mostly arises
in cirrhotic liver and is indeed the principal cause of mortal-
ity among cirrhotic patients (21). In addition, HCC has been
proven to be highly refractory to treatment (22). Unlike most
malignancies, mortality from liver cancer has increased signif-
icantly over the past 20 years (23). Around 70% of new HCC
cases worldwide (with higher prevalence in Eastern countries)
are related to chronic infection with either Hepatitis B (HBV)
or C (HCV) virus (24). Epidemiological evidence concerning the
prevalence of chronic hepatitis affected patients indicates that the
medical and economic burden of liver cancer will still increase
significantly in Western populations during the next decades (23,
25). Besides well-known risk factors, such as male gender, older
age, viral infection and genotypes, alcohol intake, diabetes, obe-
sity, increased portal hypertension, and ethnicity (20, 24, 26), little
is known about the mechanisms that favor HCC development and
progression (20).
From a molecular perspective, HCC is a highly heterogeneous
tumor reflecting under this aspect the wide range of its etiologic-
associated factors (24, 27). Unbiased molecular approaches such as
global gene expression profile (either microarray based or massive
RNA sequencing) along with DNA deep analysis (next generation
sequencing, NGS) have identified key alterations in HCC involv-
ing regulatory pathways such as Wnt/β-catenin, loss of Axin1 and
Axin2, MAPK, p14ARF/p53, p16INK4A/Rb, transforming growth
factor-β (TGF-β), and PTEN/Akt (26–29). However, although
substantial efforts have been placed in the identification of impor-
tant molecular players in hepatocarcinogenesis, currently, all HCC
cases presenting with the same stage are treated irrespectively of
their molecular subtypes. Thus, the identification of new HCC
makers is at the same time an unmet need and a great opportunity
to establish more personalized therapies. One major contribu-
tion aiming to ameliorate the current molecular classification of
HCC may occur by the integration of lncRNAs expression pro-
files into existing data sets. Up to date, a continuous growing
number of lncRNAs are described to be involved in HCC dis-
ease development and progression (1, 3, 30). In Table 1 some of
the best-characterized lncRNAs involved in HCC are shown. For
example, HULC (highly upregulated in liver cancer) expression
among the first lncRNA to be investigated in HCC is increased
in HCC samples being as well associated with histological grade
and HBV infection (31). HULC oncogenic activity in HCC has
been partially uncovered via gain and loss of function experi-
ments demonstrating that it promotes proliferation of hepatoma
cells through suppressing p18 (32). Furthermore, increased HULC
Table 1 | Examples of IncRNAs associated with liver diseases.
IncRNA Transcript (kb) Reported role in liver disease Reference
HULC 0.5 High expression in HCC is associated with tumor grade and HBV infection (31, 32)
H19 2.3 Overexpressed in HCC and peri-tumoral area, correlates with prognosis (33, 34)
MALAT-1 8.7 Increased in HCC, it is associated with metastasis and disease recurrence (35)
TUC338 0.59 Controls cell proliferation and is increased in HCC and cirrhosis (36)
HOTTIP 4.3 Highly upregulated in HCC, predics disease progression and outcome (11, 37, 40)
HOTAIR 2.3 Associated to cell invasion and chemosensitivity, predicts disease recurrence (12, 13)
IncRNA-ATB 2.7 Controls EMT via ZEB1/ZEB2, predicts survival (41)
HELLP 2.4 Linked to a Mendelian disorder with autosomal-recessive inheritance (43)
lncRNA-LALR-1 1.2 Enhance hepatocyte proliferation capacity after partial hepatectomy (44)
IncRNA DYNLRB2–2 10.2 Modulate both glucose and cholesterol metabolism in liver (45)
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levels have been also detected in the plasma of HCC patients
(33). Importantly, these findings suggest that lncRNAs in plasma
might be used as non-invasive novel biomarkers for the diagno-
sis and/or prognosis as well as monitoring of disease progression.
H19 levels, an lncRNA that is exclusively expressed by the mater-
nal allele, are associated with IGF2 (insulin-like growth factor
2) and are increased in HCC; high H19 levels are associated to
worst patients’ prognosis (34, 35). MALAT-1 (metastasis associ-
ated lung adenocarcinoma transcript 1), with a remarkable RNA
transcript length of 8.7 kb, is associated to metastasis formation
and HCC recurrence (36). TUC338 (transcribed ultra-conserved
region 338) levels are also altered in HCC and peri-tumoral
cirrhotic tissue (37). Interestingly, TUC338 knockdown reduces
tumor growth in both murine and human HCC cell lines (37).
Our group has also contributed to this field and has recently
discovered that HOTTIP, an HOXA locus associated lncRNA, is
highly upregulated in HCC and can predict both disease progres-
sion and patients’ outcome (38). HOTTIP is located in physical
contiguity (chr 7p15.2) with the transcriptional factor HOXA13
(11). Consistent with its genomic position 5′ to HOXA13, HOT-
TIP is exclusively expressed from development to adulthood in
lumbo-sacral anatomic regions (11). Via interacting with the
WDR5/MLL protein complex and guiding it to precise DNA loci,
HOTTIP directly coordinates and controls the activation of several
5′ HOXA genes (11). Furthermore, HOTAIR expression, another
HOX genes associated lncRNA that resides within the HOXC locus
close by HOXC11 and is specifically expressed in distal and poste-
rior anatomical structures, can predict HCC recurrence after liver
transplant (39). At the same time, its inhibition in vitro reduces
cell invasion and increases chemosensitivity (40). HOTAIR inter-
acts with chromatin remodeling complexes, such as PRC2 and
LSD1/CoREST-H3K4, to respectively methylate or de-methylate
DNA (13, 41). Among the latest example reported in literature, the
lncRNA-activated by TGF-(lncRNA-ATB) is upregulated in HCC
and associated with poor prognosis (42). lncRNA-ATB upregu-
lates ZEB1 and ZEB2 by competitively binding the miR-200 family
members thus inducing EMT and invasion eventually resulting in
metastasis in HCC patients. In addition, lncRNA-ATB promotes
organ colonization of disseminated tumor cells by binding IL-11
mRNA and triggering STAT3 signaling. These data suggest that
lncRNA-ATB may serve as a potential target for anti-metastatic
therapies.
One major unmet need in HCC is the lacking of clinically val-
idated response to therapy markers. When detected at an early
stage of disease, HCC patients might be still eligible for surgical-
based curative treatments (20). However, currently only 30–40%
of HCC patients are diagnosed at an early stage and are eligible
for resection, local ablation, or transplantation (20). Conversely,
when HCC is detected at an intermediate or advanced stage, no
treatment option exists besides Sorafenib (46). Sorafenib is a mul-
tityrosine kinase inhibitor that effectively blocks several receptors
activity such as VEGFR (vascular endothelial growth factor recep-
tor), PDGFR (platelet-derived growth factor receptor), and the
RAF serine/threonine kinases along the RAF/MEK/ERK path-
way (46). Nevertheless, Sorafenib has been shown a consistent
but limited survival benefit in HCC (10–12 weeks increased sur-
vival) accompanied by a number of moderate to severe side effects
(43, 46). This makes HCC somehow unique among cancers having
no standard cytotoxic therapy. Thus, it is imperative to identify
new therapeutic targets and biomarkers to predict response to
therapy. LncRNAs present as a promising new resource.
lncRNAs IN NON-NEOPLASTIC LIVER DISEASES
Although most of the so far characterized lncRNAs investigated
in liver have been shown to influence liver cancer development
and/or disease progress (1), several others lncRNA have been also
associated to non-neoplastic liver conditions. For example, using
genome-wide linkage analysis of families with HELLP syndrome,
a disorder defined as a group of symptoms that occur in pregnant
women mostly during the third trimester having recurrent hemol-
ysis, low platelet count, and markedly elevated liver enzymes, it
has been shown that such condition is associated to a specific hap-
lotype present on the 12q23 chromosome region (47). Further
studies have demonstrated that this genomic locus, more precisely
in the intergenic region between the PMCH and IGF1 genes, con-
tains an lncRNA transcript more than 205 kb in length (47). So
far, this is the first lncRNA gene to be linked to a Mendelian disor-
der with autosomal-recessive inheritance with direct effect on liver
functionality (44, 47). Furthermore, the lncRNA named LALR-1
(human ortholog hLALR-1) has been shown to enhance hepato-
cyte proliferation capacity both in vitro and in vivo, eventually
promoting liver regeneration capacity after 2/3 partial hepatec-
tomy (PH) experiments. LALR-1 facilitates cyclin D1 expression
through the activation of Wnt/β-catenin signaling via the suppres-
sion of Axin1 (45). It should be now investigated whether targeting
hLALR-1 in vivo may be therapeutically beneficial in liver failure
condition or liver transplant where sustained liver regeneration is
needed. Finally, increased liver levels of the lncRNA DYNLRB2–2
inducing GPR119G (protein-coupled receptor 119) and ABCA1
expression has been shown to modulate both glucose and choles-
terol metabolism in liver, eventually resulting in reduced athero-
sclerotic plaque progression in apoE(−/−) mice (48). These results
suggest that the modulation of DYNLRB2–2/GPR119 liver levels
might offer a therapeutic approach to prevent plaque formation
in high-risk atherosclerotic prone individuals.
lncRNAs IN LIVER DISEASES: A GLIMPSE INTO THE FUTURE
Long non-coding RNAs are increasingly recognized as essential
regulators of biological processes in normal and pathological con-
ditions thus having a high potential to serve as novel diagnostic
and prognostic tools (49). Many individual examples of disease
relevant lncRNAs have been reported, but research in the field
of liver-associated disease is somehow still left behind. Deep bio-
chemical and functional analyses of cells with specific-lncRNA
altered expression are a first step to advance toward a more com-
prehensive understating of their physiological role. However, one
major challenge for the future would be to systematically address
the distribution of lncRNAs expression among the different cellu-
lar components of the liver. Whether hepatocyte, Kupffer, endothe-
lial, or bile duct cells, it will be critical to identify where and to
what level lncRNAs are expressed within the liver. At the same
time, defining the localization of specific lncRNAs will also pro-
vide additional essential information concerning their functions.
Considering the prominent involvement of lncRNAs in HCC
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development and progression, another challenge for researchers
in the field will be to assess the lncRNAs landscape in cirrhotic
patients. This approach might eventually lead to the identifica-
tion of lncRNAs that could be used as predictive biomarkers of
disease development. To achieve this goal, a combination of clin-
ically driven, genetically defined, morphologically classified, and
molecular-based study will have to be performed. Multidiscipli-
nary research group with differential background, from clinicians
to geneticists, pathologists, molecular biologists, and biochemists,
should cooperate to successfully address these issues. To conclude,
lncRNAs will certainly provide a fruitful field of study and most
importantly a new resource for disease associated biomarkers and
molecular targets for therapy for liver diseases.
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